Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Top Republican says US officials are 'fearful' about UFO investigation
Dutch Firms Partner With Namibia to Create Green-Hydrogen Sovereign Wealth Fund
Atlantic Has Seen 73 Days of Named Storms in 2023: Weather Watch
Bitcoin ETF Euphoria Recedes While Weary Crypto Advocates Seek More Clarity
AI Demand for Nvidia Chips Keeps Rising. New China Restrictions Are Likely Just Noise.
Fidelity’s Vast Trove of Data Coveted by Tech Firms in Age of AI
AI Is the Stock Market’s ‘New Growth Thing,’ Citi’s Chronert Says
Age of Learning Curriculum Board Member Dr. Rebecca Palacios Honored by National Board for Professional Teaching Standards with James A. Kelly Award